MCR - Neotrip

Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative Locally Advanced Breast Cancer undergoing treatment with nab-paclitaxel and carboplatin.

PHASE

III

NCT Number

NCT02620280

DEFINITION

Pharmacological

SPONSOR

Fondazione Michelangelo